NCT00394953View on ClinicalTrials.gov

A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

490

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Anemia
Interventions
DRUG

Darbepoetin alfa

As prescribed, iv.

DRUG

methoxy polyethylene glycol-epoetin beta [Mircera]

120, 200 or 360 micrograms iv / month, starting dose

Trial Locations (88)

1003

Lausanne

1020

Brussels

1090

Vienna

1200

Brussels

1220

Vienna

2250

Gosford

3052

Parkville

3186

Clayton

3400

Hillerød

4000

Roskilde

4010

Linz

4102

Woolloongabba

5001

Aarau

8800

Roeselare

9100

Aalborg

9300

Aalst

14004

Córdoba

14202

Hérouville-Saint-Clair

16132

Genova

20521

Turku

21079

Dijon

22027

Saint-Brieuc

22100

Como

23900

Lecco

24071

León

27100

Pavia

28003

Madrid

28035

Madrid

28040

Madrid

28041

Madrid

28046

Madrid

28222

Madrid

30029

Nîmes

30122

Venezia

32000

Auch

32005

Ourense

33000

Bordeaux

33521

Tampere

34170

Castelnau-le-Lez

34295

Montpellier

35033

Rennes

36204

Vigo

36205

Vigo

36251

Bad Hersfeld

38701

La Tronche

39008

Santander

40138

Bologna

41100

Modena

44093

Saint-Herblain

44263

Dortmund

48013

Bilbao

50047

Prato

51092

Reims

53127

Bonn

62321

Boulogne

63400

Chamalières

69100

Villeurbanne

69437

Lyon

70191

Stuttgart

75015

Paris

75970

Paris

78054

Villingen-Schwenningen

80804

München

91712

Fleury-Mérogis

93400

Saint-Ouen

95303

Cergy-Pontoise

SA 5000

Adelaide

T2N 2T9

Calgary

L8N 4A6

Hamilton

N2G 1N9

Kitchener

L5M 2V8

Mississauga

K1H 7W9

Ottawa

M5G 2C4

Toronto

J4V 2H1

Greenfield Park

G8Z 4K8

Trois-Rivières

1081 HV

Amsterdam

3318 AT

Dordrecht

2400-441

Leiria

03010

Alicante

08915

Badalona

08003

Barcelona

08036

Barcelona

BT9 7LJ

Belfast

CT1 3NE

Canterbury

G4 OSF

Glasgow

SE22 8PT

London

M13 9WL

Manchester

TR1 3LJ

Truro

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00394953 - A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients | Biotech Hunter | Biotech Hunter